Loading
MT
Mabvax Therapeutics Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HANSEN JOHN DAVID, was filed 02 Aug 2017.
Mabvax Therapeutics Holdings, Inc.: what insiders have been doing
Mabvax Therapeutics Holdings, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Mabvax Therapeutics Holdings, Inc. has had no insider filing for more than a year; the last one goes back to 4 April 2018.
Since 2016, the database holds 10 purchases and 49 sales by insiders of the company.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
100
Thresholds
n/a
Buy Volume
€17,997
10 ops. · all time
Sell Volume
€709,501
49 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2017FY ended December 2017 · cache
Income statement
Net income-17M
Last declaration on 4 April 2018
Declarations100 total
513 shares0Common StockSEC:0001415889-18-000546:0
513 shares0Common StockSEC:0001415889-18-000550:0
513 shares0Common StockSEC:0001415889-18-000541:0
7,021 shares0Common StockSEC:0001415889-18-000538:0
2,428 shares0Common StockSEC:0001415889-18-000538:1
13,561 shares0Common StockSEC:0001415889-18-000537:0
4,689 shares0Common StockSEC:0001415889-18-000537:1
513 shares0Common StockSEC:0001415889-18-000540:0
513 shares0Common StockSEC:0001415889-18-000544:0
5,015 shares0Common StockSEC:0001415889-18-000539:0
1,735 shares0Common StockSEC:0001415889-18-000539:1
17,449 shares@ US$0.8750.2% of flowCommon StockSEC:0001415889-18-000116:0
17,999 shares@ US$0.8449.8% of flowCommon StockSEC:0001415889-18-000116:1
17,444 shares@ US$0.8750.2% of flowCommon StockSEC:0001415889-18-000120:0
17,998 shares@ US$0.8449.8% of flowCommon StockSEC:0001415889-18-000120:1
17,444 shares@ US$0.8750.2% of flowCommon StockSEC:0001415889-18-000114:0
17,996 shares@ US$0.8449.8% of flowCommon StockSEC:0001415889-18-000114:1
17,445 shares@ US$0.8750.2% of flowCommon StockSEC:0001415889-18-000118:0
17,996 shares@ US$0.8449.8% of flowCommon StockSEC:0001415889-18-000118:1
38,054 shares@ US$0.9221.8% of flowCommon StockSEC:0001415889-18-000083:0
41,873 shares@ US$0.9221.1% of flowCommon StockSEC:0001415889-18-000080:0
59,263 shares@ US$0.9218.6% of flowCommon StockSEC:0001415889-18-000082:0
3,071 shares@ US$0.9225.0% of flowCommon StockSEC:0001415889-18-000081:0
449,159 shares0Common StockSEC:0001415889-18-000064:0
406,382 shares0Common StockSEC:0001415889-18-000062:0
25 of 100 declarations
About Mabvax Therapeutics Holdings, Inc.
Mabvax Therapeutics Holdings, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer. It is listed on NASDAQ under the symbol MBVX.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
